Asthma remains one of the most prevalent chronic diseases in the US. 3 Although poor adherence substantially contributes to inadequate outcomes, even patients with high adherence often experience ...
HealthDay News — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled ...
Chiesi is the first pharmaceutical company to have demonstrated with randomized clinical trials, two of which published in The Lancet 1,2, the efficacy of the triple extrafine combination to prevent ...
(HealthDay News) — For patients with chronic obstructive pulmonary disease (COPD), once-daily single-inhaler triple therapy is better for lung function and health-related quality of life than inhaled ...
Findings support the most recent Global Initiative for Chronic Obstructive Lung Disease recommendations and the European Respiratory Society Task Force report on ICS withdrawal in COPD. The study ...
Changing patients from an inhaled corticosteroid (ICS)/long-acting β agonist (LABA) inhaler and long-acting muscarinic agonist (LAMA) inhaler to a LAMA/LABA inhaler and a separate ICS inhaler did not ...
Stakeholders in healthcare consider the implications for treating chronic obstructive pulmonary disease with triple therapy based on data demonstrated in the IMPACT and FULFIL trials. Transcript Neil ...
Please provide your email address to receive an email when new articles are posted on . Among new initiators of multiple-inhaler triple therapy for asthma, discontinuation was high, although ...
Triple therapy for COPD, vs ICS/LABA therapy, was independently associated with ischemic heart disease, heart failure, arrhythmia, and atrial fibrillation/flutter. Cardiovascular events in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback